TrialIntensive care medicine2022

Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial.

G Bellingan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.